These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35234695)

  • 21. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
    Boorjian SA; Karnes RJ; Viterbo R; Rangel LJ; Bergstralh EJ; Horwitz EM; Blute ML; Buyyounouski MK
    Cancer; 2011 Jul; 117(13):2883-91. PubMed ID: 21692049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.
    Boeri L; Sharma V; Kwon E; Stish BJ; Davis BJ; Karnes RJ
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):514-523. PubMed ID: 33268854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between Peripheral Thromboembolic Vascular Disease and Androgen Deprivation Therapy in Asian Prostate Cancer Patients.
    Lu YC; Huang CY; Yeh HM; Hong JH; Chang CH; Muo CH; Chung SD; Yang TK; Jaw FS; Chung CJ
    Sci Rep; 2019 Oct; 9(1):14231. PubMed ID: 31578427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: A meta-analysis.
    Guo L; Zhu Z; Zhang X
    Medicine (Baltimore); 2020 Mar; 99(10):e19153. PubMed ID: 32150055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy.
    Sun G; Huang R; Zhang X; Shen P; Gong J; Zhao J; Liu J; Tang Q; Shu K; Yin X; Chen N; Zeng H
    Prostate; 2017 Sep; 77(12):1279-1287. PubMed ID: 28752514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
    Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
    Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy.
    Dai B; Qu YY; Kong YY; Ye DW; Yao XD; Zhang SL; Zhang HL; Yang WY
    Asian J Androl; 2013 Jul; 15(4):466-70. PubMed ID: 23708460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer.
    Lu YC; Huang CY; Cheng CH; Huang KH; Lu YC; Chow PM; Chang YK; Pu YS; Chen CH; Lu SL; Lan KH; Jaw FS; Chen PL; Hong JH
    Sci Rep; 2022 Jul; 12(1):12480. PubMed ID: 35864293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry.
    Garcia-Rodriguez J; Fernandez-Gomez JM; Cozar JM; Miñana B; Gomez-Veiga F; Rodriguez-Antolin A; ;
    Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):156-163. PubMed ID: 32113829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laparoscopic Radical Prostatectomy Plus Extended Lymph Node Dissection in Combination With Immediate Androgen Deprivation Therapy for Cases of pT3-4N0-1M0 Prostate Cancer: A Multimodal Study of 8 Years' Follow-up.
    Yang Y; Luo Y; Hou GL; Huang QX; Pang J; Gao X
    Clin Genitourin Cancer; 2016 Aug; 14(4):e321-7. PubMed ID: 26691668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
    Xu Z; Wei F; Wang J; Ma S; Kan Y; Li B; Qi N; Mao L
    Cancer Med; 2023 Feb; 12(4):4352-4356. PubMed ID: 36106643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
    Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
    Woon DTS; Herrera-Cáceres JO; Goldberg H; Shiakh H; Whelan E; Nason G; Ajib K; Tan GH; Chandrasekar T; Alhunaidi O; Finelli A; Zlotta A; Berlin A; Diamantis E; Fleshner N
    J Urol; 2020 Aug; 204(2):289-295. PubMed ID: 32068483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?
    Krahn M; Bremner KE; Tomlinson G; Luo J; Ritvo P; Naglie G; Alibhai SM
    BJU Int; 2011 Nov; 108(10):1588-96. PubMed ID: 21453344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
    Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
    Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
    Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.